Axicabtagene ciloleucel: Updated Ph I/II ZUMA-1 data

Updated data from 101 patients with chemorefractory aggressive B cell NHL in the modified intent-to-treat (mITT) population of the open-label, U.S. and Israeli Phase I/II ZUMA-1 trial showed that a single IV infusion of axicabtagene ciloleucel led to an ORR of 44% and a complete response rate of 39% at a median follow-up of 8.7 months. Median duration of response was 8.2 months in the overall population and was not reached for patients who had a complete response. Median OS was also not reached and the 6-month survival rate was 80%. The trial is evaluating axicabtagene ciloleucel in patients with diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma and primary mediastinal B cell lymphoma (PMBCL). Data were presented at the American Association for Cancer Research meeting in Washington, D.C. Kite has previously reported data from the trial (see BioCentury, Nov. 23, 2015; Dec. 14, 2015; June 20, 2016; Oct. 3, 2016 & March 10, 2017)...